530-531 / 1778
Conclusions
CTRT vs RT for high-risk endometrial cancer:
•
Improved 5-year FFS, no overall survival benefit
•
All patients 7% FFS benefit with CTRT
•
Stage III: 11% FFS benefit with CTRT
•
Significantly more toxicity with CTRT in the first 12 months
•
OS analysis may need longer follow-up